Cerus Corporation: Q1 2021 Form 10-Q Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System for pathogen reduction of blood components. Commercial products include platelet and plasma systems and, following FDA approval in November 2020, the cryoprecipitation system used to produce pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC). The red blood cell system remains in development.
This unaudited Form 10-Q covers the three months ended March 31, 2021, compared with the three months ended March 31, 2020. Cerus operates in one blood-safety segment and reported 171.2 million common shares outstanding as of April 21, 2021.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Product revenue | $23.4 million | $18.6 million | Up 26% |
| Government contract revenue | $6.2 million | $6.0 million | Up 3% |
| Total revenue | $29.6 million | $24.6 million | Up 20% |
| Gross profit on product revenue | $12.3 million | $10.3 million | Up 19% |
| Product gross margin | 53% | 55% | Down 2 percentage points |
| Research and development expense | $15.7 million | $15.8 million | Down 0.4% |
| Selling, general and administrative expense | $19.2 million | $15.9 million | Up 20% |
| Loss from operations | $(16.4) million | $(15.4) million | Loss increased |
| Net loss | $(17.5) million | $(16.5) million | Loss increased 6% |
| Net loss per share | $(0.10) | $(0.10) | Unchanged |
| Net cash used in operations | $(18.0) million | $(19.8) million | Use improved |
Product revenue growth was driven primarily by higher U.S. disposable platelet kit volumes, increased plasma kit sales in Europe and the Middle East, and favorable euro exchange rates. Two customers, Établissement Français du Sang and the American Red Cross, each represented 22% of product revenue in Q1 2021.
Cash, cash equivalents and restricted cash totaled $59.8 million at March 31, 2021, compared with $38.9 million at December 31, 2020. Cash and short-term investments totaled $131.7 million, while total liquidity including restricted cash was $133.9 million, compared with $135.9 million at year-end 2020. Working capital was $126.5 million.
Investing activities provided $21.4 million, primarily from investment maturities and sales. Financing activities provided $17.5 million, including $15.0 million from a new term-loan tranche. Capital expenditures were $0.2 million.
Total debt was $64.6 million at March 31, 2021, including $55.0 million of term-loan principal and $9.9 million drawn under the revolving facility. The term loan had an effective interest rate of approximately 7.50% and matures in March 2024. The company was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Total revenue increased $4.9 million, led by a $4.8 million increase in product revenue.
- Product gross margin declined to 53% from 55% because of unfavorable product mix and foreign exchange effects.
- SG&A increased $3.3 million, primarily due to higher stock-based compensation and investment ahead of the PRCFC commercial launch.
- R&D expense was essentially flat, while operating loss increased by $1.0 million and net loss increased by $1.0 million.
- Operating cash use improved by $1.8 million, reflecting increased product sales and collections, partly offset by inventory-related payments.
- Debt increased by $16.5 million from December 31, 2020, primarily due to the $15.0 million term-loan draw and higher revolving borrowings.
- Shares outstanding increased during the quarter through option exercises, restricted stock vesting and employee stock-purchase activity. No shares were sold under the $100.0 million at-the-market equity facility.
Guidance, outlook, management commentary and risks
- Management expects product revenue to increase over future periods from continued U.S. sales expansion, broader adoption and commercialization efforts. Management also planned a limited 2021 launch of PRCFC to U.S. hospitals.
- Management expected BARDA revenue to increase or remain flat over the following three to six months, subject to the effect of COVID-19 on funded activities.
- BARDA had committed up to $116.9 million as of March 31, 2021, with potential total funding of up to $213.9 million through December 31, 2021 if additional options are exercised. The company remains responsible for approximately $5.0 million of co-investment and potentially an additional $9.6 million.
- COVID-19 delayed enrollment in the RedeS and ReCePI red blood cell studies, post-approval platelet studies and other development activities. Further delays could affect regulatory submissions, BARDA funding and cash flows.
- The red blood cell system is not commercialized. Cerus does not expect a European approval decision before 2022, if ever, and additional U.S. clinical and in-vitro work remains necessary.
- PRCFC commercialization initially remains limited by the geographic coverage of manufacturing partners and their pending biologics license applications. Cerus has limited experience selling finished biologic products directly to hospitals.
- The FDA platelet safety guidance required blood centers to comply by October 1, 2021. Adoption may favor Cerus, but customers could choose alternative permitted approaches, particularly if supply, implementation resources or product configurations are inadequate.
- Cerus relies heavily on Fresenius and other sole or limited-source suppliers. Supply interruptions, component obsolescence, quality failures, regulatory audits or COVID-19 disruptions could limit production and increase costs.
- The company expects continuing losses and stated that profitability may never be achieved. Management believes available liquidity, product receipts and government-contract funding are sufficient for at least the next 12 months, but this conclusion depends on assumptions regarding revenue, BARDA funding and capital-market access.
- Material commitments included $29.4 million of short-term and $3.0 million of long-term purchase commitments, in addition to operating leases with $27.1 million of undiscounted future payments.
- The filing reported no legal proceedings, no off-balance-sheet arrangements and no material changes to disclosure controls; management concluded disclosure controls were effective as of March 31, 2021.
Important facts for investors to verify
- Whether U.S. platelet adoption accelerated after the October 1, 2021 FDA compliance date and whether Cerus could meet resulting demand.
- The pace and economics of the PRCFC launch, including manufacturing-partner BLA approvals, hospital adoption, reimbursement and product-expiration exposure.
- Progress, enrollment and safety results for the RedeS, ReCePI and required platelet post-approval studies.
- Whether BARDA exercises additional options, extends performance periods or reduces, delays or terminates funding.
- Cash burn, debt amortization beginning in 2022, covenant compliance and the timing or terms of any future financing.
- Dependence on Fresenius and other sole-source suppliers, including resolution of component obsolescence and manufacturing-quality issues.
- Regulatory requirements under the European MDR for existing products and the red blood cell system.
- Customer concentration, foreign-exchange effects and the sustainability of sales to the American Red Cross and Établissement Français du Sang.